

BEST AVAILABLE COPY

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

USAN 11/501,464
For IDS filed 11/10/06

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07C 217/52, A61K 31/135 C07C 229/14, 237/06 A61K 31/22, 31/16		A1	(11) International Publication Number: WO 94/07843 (43) International Publication Date: 14 April 1994 (14.04.94)
(21) International Application Number: PCT/GB93/01961 (22) International Filing Date: 16 September 1993 (16.09.93)		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority data: 9220286.0 25 September 1992 (25.09.92) GB		Published With international search report.	
(71) Applicant (<i>for all designated States except US</i>): MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB).			
(72) Inventor; and (75) Inventor/Applicant (<i>for US only</i>) : TEALL, Martin, Richard [GB/GB]; 55 Lower Street, Stansted, Essex CM24 8LN (GB).			
(74) Agent: QUILLIN, Helen, Kaye; Merck & Co., Inc., European Patent Department, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).			

(54) Title: CYCLOHEXYL AMINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS



(57) Abstract

Compounds of formula (I), and salts and prodrugs thereof wherein X represents O or S; R¹ represents optionally substituted phenyl; R² represents optionally substituted phenyl; R³ and R⁴ each independently represent H, COR^a, CO₂R^a or C₁₋₆alkyl optionally substituted by a group selected from (CO₂R^a, CONR^aR^b, hydroxy, cyano, COR^a, NR^aR^b, and phenyl optionally substituted by C₁₋₆alkyl, C₁₋₆alkoxy, halo or trifluoromethyl); R⁵ represents H or XCH₂R⁶ wherein R⁶ represents optionally substituted phenyl and X is as previously defined; R⁷ and R⁸ are each H or C₁₋₆alkyl; and R^a and R^b each independently represent H, C₁₋₆alkyl, phenyl or trifluoromethyl; are tachykinin receptor antagonists useful in therapy.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

- 1 -

CYCLOHEXYL AMINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS

This invention relates to a class of cyclic
5 compounds, which are useful as tachykinin antagonists.
More particularly, the compounds of the invention
comprise a cyclohexyl ring system substituted by an
arylmethoxy or arylmethylthio moiety, phenyl and an
optionally substituted amino group.

10 The tachykinins are a group of naturally-
occurring peptides found widely distributed throughout
mammalian tissues, both within the central nervous system
and in the peripheral nervous and circulatory systems.
The three known mammalian tachykinins are:

15 substance P, neurokinin A and neurokinin B:

Evidence for the usefulness of tachykinin
receptor antagonists in pain, headache, especially
migraine, Alzheimer's disease, multiple sclerosis,
attenuation of morphine withdrawal, cardiovascular
20 changes, oedema, such as oedema caused by thermal injury,
chronic inflammatory diseases such as rheumatoid
arthritis, asthma/bronchial hyperreactivity and other
respiratory diseases including allergic rhinitis,
inflammatory diseases of the gut including ulcerative
25 colitis and Crohn disease, ocular injury and ocular
inflammatory diseases, proliferative vitreoretinopathy,
irritable bowel syndrome and disorders of bladder
function including cystitis and bladder detruser hyper-
reflexia is reviewed in "Tachykinin Receptors and
30 Tachykinin Receptor Antagonists", C.A. Maggi, R.
Patacchini, P. Rovero and A. Giachetti, J. Auton.
Pharmacol. (1993) 13, 23-93. Tachykinin antagonists are
also believed to be useful in allergic conditions
[Hamelet et al Can. J. Pharmacol. Physiol. (1988) 66

- 2 -

1361-7], immunoregulation [Lotz et al Science (1988) 241
1218-21 and Kimball et al, J. Immunol. (1988) 141 (10)
3564-9], and as anticonvulsants [Garant et al., Brain
Research (1986) 382 372-8]. Tachykinin antagonists may
5 also be useful in the treatment of small cell carcinomas,
in particular small cell lung cancer (SCLC) [Langdon et
al., Cancer Research (1992) 52, 4554-7].


It has furthermore been suggested that
tachykinins have utility in the following disorders:
10 depression, dysthymic disorders, chronic obstructive
airways disease, hypersensitivity disorders such as
poison ivy, vasospastic diseases such as angina and
Reynaud's disease, fibrosing and collagen diseases such
as scleroderma and eosinophilic fascioliasis, reflex
15 sympathetic dystrophy such as shoulder/hand syndrome,
addiction disorders such as alcoholism, stress related
somatic disorders, neuropathy, neuralgia, disorders
related to immune enhancement or suppression such as
systemic lupus erythematosus (European patent application
20 no. 0 436 334), conjunctivitis, vernal conjunctivitis,
contact dermatitis, atropic dermatitis, urticaria, and
other eczematoid dermatitis (European patent application
no. 0 394 989) and emesis (European patent application
no. 0 533 280).

25 We have now found a class of non-peptides which
are potent antagonists of tachykinin.

European patent application no. 0 436 334
discloses 4- to 7-membered azacyclic compounds
substituted at the 3-position by a benzyl substituted
30 amino moiety and at the 2-position by an aryl moiety.
The compounds are said to be tachykinin antagonists.

The present invention provides a compound of
formula (I), or a salt or prodrug thereof:

- 3 -



(I)

10 wherein

X represents O or S;

15 R¹ represents phenyl optionally substituted by 1, 2 or 3 groups selected from C₁-6alkyl, C₂-6 alkenyl, C₂-6alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, -OR^a, SR^a, SOR^a, SO₂R^a, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -CO₂R^a or -CONR^aR^b;

20 R² represents phenyl optionally substituted by C₁-6alkyl, C₁-6alkoxy, halo or trifluoromethyl;

25 R³ and R⁴ each independently represent H, COR^a, CO₂R^a or C₁-6alkyl optionally substituted by a group selected from (CO₂R^a, CONR^aR^b, hydroxy, cyano, COR^a, NR^aR^b, and phenyl optionally substituted by C₁-6alkyl, C₁-6alkoxy, halo or trifluoromethyl);

30 R⁵ represents H or XCH₂R⁶ wherein R⁶ represents phenyl optionally substituted by 1, 2 or 3 groups selected from C₁-6alkyl, C₂-6 alkenyl, C₂-6alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, -OR^a, SR^a, SOR^a, SO₂R^a, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -CO₂R^a or -CONR^aR^b and X is as previously defined;

35 R⁷ and R⁸ each independently represent H or C₁-6alkyl; and

R^a and R^b each independently represent H, C₁-6alkyl, phenyl or trifluoromethyl.

- 4 -

As used herein, the definition of each expression, when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.

5 The alkyl, alkenyl and alkynyl groups referred to with respect to the above formula may represent straight, branched or cyclic groups or combinations thereof. Thus, for example, suitable alkyl groups include methyl, ethyl, n- or iso-propyl, n-, sec-, iso-
10 or tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and cycloalkyl-alkyl groups such as cyclopropylmethyl; suitable alkenyl groups include vinyl and allyl; and suitable alkynyl groups include propargyl.

15 The term "halo" as used herein includes fluoro, chloro, bromo and iodo, especially chloro and fluoro.

A subgroup of compounds according to the invention is represented by compounds of formula (I) wherein R⁷ and R⁸ each represent H, and salts and prodrugs thereof.

20 Preferably X represents O.

Preferably R¹ represents substituted phenyl. When R¹ is substituted phenyl suitable substituents include C₁₋₆alkyl, nitro, trifluoromethyl, trimethylsilyl, bromo, chloro, fluoro, iodo, cyano, methyl, ethyl, cyclopropyl, vinyl, methoxy, phenoxy, amino and carbonylmethoxy. Preferably R¹ represents phenyl substituted by one or more groups selected from methyl and trifluoromethyl. More preferably R¹ represents disubstituted phenyl, especially 3,5-dimethylphenyl or 3,5-bis(trifluoromethyl)phenyl.

25 Preferably R² represents unsubstituted phenyl.

Suitable values for R³ and R⁴ include H, C₁₋₆alkyl, such as methyl, and substituted C₁₋₆alkyl, such as C₁₋₆alkyl, preferably CH₁₋₄alkyl, more preferably

- 5 -

CH_2 , substituted by $\text{CONR}^{10}\text{R}^{11}$, especially CONH_2 , or CO_2R^a , such as CO_2CH_3 .

5 Preferably at least one of R^3 and R^4 represents H. More preferably one of R^3 and R^4 represents H and the other of R^3 and R^4 represents H or CH_2CONH_2 .

Preferably R^5 represents H.

For use in medicine, the salts of the compounds of formula (I) will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of 10 the compounds according to the invention (such as the dibenzoyltartrate salts) or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by 15 mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, oxalic acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic 20 acid, phosphoric acid or p-toluenesulphonic acid. Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl or aralkyl moiety. Furthermore, where the compounds of the 25 invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts.


30 The present invention includes within its scope prodrugs of the compounds of formula (I) above. In general, such prodrugs will be functional derivatives of the compounds of formula (I) which are readily convertible in vivo into the required compound of formula

- 6 -

(I). Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

5 The compounds according to the invention may exist both as enantiomers and as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.

10 A particular sub-class of compounds according to the invention is represented by compounds of formula (Ia), and salts and prodrugs thereof:



(Ia)

wherein R², R³ and R⁴ are as defined for formula (I); and R²⁰ and R²¹ independently represent H

25 C₁-6alkyl, C₂-6alkenyl, C₂-6alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a, SR^a SOR^a, SO₂R^a, NR^aR^b, NR^aCOR^b, NR^aCO₂R^b, COR^a or CONR^aR^b, where R^a and R^b are as previously defined.

30 Preferably R²⁰ and R²¹ are selected from H, C₁-6alkyl, such as t-butyl, ethyl or methyl, C₁-6alkoxy, such as methoxy, halo, such as chloro, bromo or iodo, and trifluoromethyl.

The substance P antagonising activity of the compounds described herein was evaluated using the human NK1R assay described in published European patent

- 7 -

application no. 0 528 495. The method essentially involves determining the concentration of the test compound required to reduce by 50% the amount of radiolabelled substance P binding to human NK1R, thereby 5 affording an IC₅₀ value for the test compound. The compounds of Examples 1, 5 and 6 were found to have IC₅₀ values of 100nM, 350nM and 100nM, respectively.

The invention also provides pharmaceutical compositions comprising one or more compounds of this 10 invention in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal 15 administration, or topical administration including administration by inhalation or insufflation.

The invention further provides a process for the preparation of a pharmaceutical composition comprising a compound of formula (I), or a salt or 20 prodrug thereof, and a pharmaceutically acceptable carrier, which process comprises bringing a compound of formula (I), or a salt or prodrug thereof into association with a pharmaceutically acceptable carrier.

For preparing solid compositions such as 25 tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tabletting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other 30 pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as

- 8 -

homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

- 9 -

Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions 5 may contain suitable pharmaceutically acceptable excipients as set out above. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably sterile pharmaceutically acceptable solvents may be 10 nebulised by use of inert gases. Nebulised solutions may be breathed directly from the nebulising device or the nebulising device may be attached to a face mask, tent or intermittent positive pressure breathing machine. Solution, suspension or powder compositions may be 15 administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.

For topical administration, for example as a cream, ointment or lotion, pharmaceutically acceptable carriers are, for example, water, mixtures of water and 20 water-miscible solvents such as lower alkanols or arylalkanols, vegetable oils, polyalkylene glycols, petroleum based jelly, ethyl cellulose, ethyl oleate, carboxymethylcellulose, polyvinylpyrrolidone, isopropyl myristate and other conventionally-employed non-toxic, 25 pharmaceutically acceptable organic and inorganic carriers. The pharmaceutical preparation may also contain non-toxic auxiliary substances such as emulsifying, preserving, wetting agents, bodying agents and the like, as for example, polyethylene glycols 200, 300, 400 and 600, carbowaxes 1,000, 1,500, 4,000, 6,000 and 10,000, antibacterial components such as quaternary ammonium compounds, phenylmercuric salts known to have cold sterilizing properties and which are non-injurious in use, thimerosal, methyl and propyl paraben, benzyl

- 10 -

alcohol, phenyl ethanol, buffering ingredients such as sodium chloride, sodium borate, sodium acetates, gluconate buffers, and other conventional ingredients such as sorbitan monolaurate, triethanolamine, oleate, 5 polyoxyethylene sorbitan monopalmitate, dioctyl sodium sulfosuccinate, monothioglycerol, thiosorbitol, ethylenediamine tetraacetic acid, and the like.

The compounds of formula (I) are of value in the treatment of a wide variety of clinical conditions 10 which are characterised by the presence of an excess of tachykinin, in particular substance P, activity. These may include disorders of the central nervous system such as anxiety, depression, psychosis and schizophrenia; epilepsy; neurodegenerative disorders such as dementia, 15 including senile dementia of the Alzheimer type, Alzheimer's disease and Down's syndrome; demyelinating diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease) and other neuropathological disorders such as peripheral 20 neuropathy, for example, diabetic or chemotherapy-induced neuropathy, and postherpetic and other neuralgias; small cell carcinoma such as small cell lung cancer; respiratory diseases such as chronic obstructive airways disease, bronchopneumonia, bronchospasm and asthma; 25 inflammatory diseases such as inflammatory bowel disease, irritable bowel syndrome, psoriasis, fibrosis, osteoarthritis and rheumatoid arthritis; allergies such as eczema and rhinitis; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as 30 conjunctivitis, vernal conjunctivitis, and the like, and proliferative vitreoretinopathy; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis; oedema, such as oedema caused by thermal injury; addiction disorders such as

- 11 -

alcoholism; stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; dysthymic disorders; adverse immunological reactions such as rejection of transplanted tissues and disorders
5 related to immune enhancement or suppression such as systemic lupus erythematosis; gastrointestinal (GI) disorders and diseases of the GI tract such as disorders associated with the neuronal control of viscera such as ulcerative colitis, Crohn's disease and incontinence;
10 emesis, including acute, delayed and anticipatory emesis, for example, induced by chemotherapy, radiation, toxins, pregnancy, vestibular disorders, surgery, migraine and variations in intracranial pressure; disorders of bladder function such as cystitis and bladder detrusor hyper-
15 reflexia; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused by vasodilation and vasospastic diseases such as angina, migraine and Reynaud's disease; and pain or nociception, for example, that attributable
20 to or associated with any of the foregoing conditions, especially the transmission of pain in migraine.

The compounds of formula (I) are particularly useful in the treatment of pain or nociception and/or inflammation and disorders associated therewith such as,
25 for example, neuropathy, such as diabetic and chemotherapy-induced neuropathy, postherpetic and other neuralgias, asthma, osteoarthritis, rheumatoid arthritis and especially migraine.

The present invention further provides a compound of formula (I) for use in therapy.
30

According to a further or alternative aspect, the present invention provides a compound of formula (I) for use in the manufacture of a medicament for the

- 12 -

treatment of physiological disorders associated with an excess of tachykinins, especially substance P.

The present invention also provides a method for the treatment or prevention of physiological disorders associated with an excess of tachykinins, especially substance P, which method comprises administration to a patient in need thereof of a tachykinin reducing amount of a compound of formula (I) or a composition comprising a compound of formula (I).

For the treatment of certain conditions it may be desirable to employ a compound according to the present invention in conjunction with another pharmacologically active agent. For example, for the treatment of respiratory diseases such as asthma, a compound of formula (I) may be used in conjunction with a bronchodilator, such as a β_2 -adrenergic receptor antagonist or tachykinin antagonist which acts at NK-2 receptors. The compound of formula (I) and the bronchodilator may be administered to a patient simultaneously, sequentially or in combination.

The present invention accordingly provides a method for the treatment of a respiratory disease, such as asthma, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula (I) and an effective amount of a bronchodilator.


The present invention also provides a composition comprising a compound of formula (I), a bronchodilator, and a pharmaceutically acceptable carrier.

In the treatment of the conditions associated with an excess of tachykinins, a suitable dosage level is about 0.001 to 50 mg/kg per day, in particular about 0.01 to about 25 mg/kg, such as from about 0.05 to about 10

- 13 -

mg/kg per day. For example, in the treatment of conditions involving the neurotransmission of pain sensations, a suitable dosage level is about 0.001 to 25 mg/kg per day, preferably about 0.005 to 10 mg/kg per day, and especially about 0.005 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.

The compounds according to the invention wherein R³ and R⁴ both represent H may be prepared by a process which comprises treatment of an intermediate of formula (II):



(II)

wherein R¹, R⁵, R⁷, R⁸ and X are as defined for formula (I) and R³⁰ represents an alkyl or, preferably, a phenyl group, with a reagent of formula R²-M, where R² is as defined for formula (I) and M represents an alkali metal, such as lithium.

The reaction is conveniently effected in a suitable organic solvent, such as an ether, for example, tetrahydrofuran.


Compounds of formula (I) where one or both of R³ and R⁴ are other than H may be prepared from compounds of formula (I) wherein both of R³ and R⁴ represent H by conventional procedures; for example, reaction with a suitable alkylating or acylating agent. Suitable procedures are described in the accompanying examples,

- 14 -

and further procedures will be readily apparent to those skilled in the art.

Intermediates of formula (II) may be prepared from compounds of formula (III):


5



(III)

wherein R¹, R⁵, R⁷, R⁸ and X are as defined for formula (I), by reaction with a compound of formula R³⁰-S-S-R³⁰ in the presence of ammonia and a nitrite, such as, for example, silver nitrite.

Compounds of formula (III) may be prepared by oxidation of the corresponding alcohols of formula (IV):




(IV)

wherein R¹, R⁵, R⁷, R⁸ and X are as previously defined, by conventional methods.


30 Conveniently the oxidation is effected under Swern conditions, i.e. with the use of oxalyl chloride in the presence of dimethyl sulphoxide. Other suitable oxidation procedures will be readily apparent to those skilled in the art.

- 15 -

Compounds of formula (IV) may be prepared by reaction of compounds of formula (V) with compounds of formula (VI):



(V)




(VI)

wherein R^1 , R^5 , R^7 , R^8 and X are as previously defined, in the presence of a base.


15 Suitable bases of use in reaction include metal hydrides, such as, for example, potassium hydride, and alumina.

The compound of formula (V) wherein R^5 is H is commercially available.

20 The compounds of formula (V) wherein R^5 is XCH_2R^6 may be prepared by reaction of a compound of formula (VII) with a compound of formula (VIII):



(VII)



(VIII)

30 wherein X and R^1 are as previously defined and L represents a leaving group such as halo, for example, bromo or iodo.

Compounds of formulae (VII) and (VIII) are commercially available or may be prepared from

- 16 -

commercially available starting materials by known procedures.

Where the above-described process for the preparation of the compounds according to the invention gives rise to mixtures of stereoisomers these isomers may, if desired, be separated, suitably by conventional techniques such as preparative chromatography.

During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

The following Examples illustrate the preparation of compounds according to the invention.

- 17 -

EXAMPLE 1

1-(3,5-Dimethylbenzyloxy)-2-amino-2-phenylcyclohexane

- 5 a) A toluene (70ml) solution containing cyclohexene oxide (20g), 3,5-dimethylbenzyl alcohol and alumina (5g) was heated at reflux for 16h with azeotropic removal of water. The solution was filtered and the solvent removed in vacuo to give 1-(3,5-dimethylbenzyloxy)-2-hydroxycyclohexane as an oil.
- 10 b) The product of Example 1a (10g) was oxidised under standard Swern conditions (JOC, 1978, 43, 2480) using oxalyl chloride (4.12ml) and dimethyl sulphoxide (6.7ml). The product was purified on silica gel eluting with petroleum ether-ethyl acetate mixtures to give 1-(3,5-dimethylbenzyloxy)-2-cyclohexanone as an oil. ^1H NMR (360MHz, CDCl_3) δ 1.61-1.96 (6H, m), 2.16-2.27 (1H, m), 2.30 (6H, s), 2.52-2.57 (1H, m), 3.85-3.90 (1H, m), 4.39, 4.68 (2H, ABq, $J = 11.6\text{Hz}$), 6.97 (2H, s) and 6.92 (1H, s).
- 15 c) The product of Example 1b (6.90g) was converted into the corresponding sulphenimine using the procedure of Davis (JOC, 1973, 38, 2809) by treatment with silver nitrate (4.9g), phenyl disulphide (6.5g) and ammonia. The crude product was purified on silica gel eluting with petroleum ether-ethyl acetate mixtures to give 1-(3,5-dimethylbenzyloxy)-2-phenyl sulphenimine cyclohexane. ^1H NMR (360MHz, CDCl_3) δ 1.42-1.62 (2H, m), 1.68-1.76 (1H, m), 1.86-1.93 (2H, m), 2.07-2.12 (1H, m), 2.30 (6H, s), 2.44-2.64 (2H, m), 4.03 (1H, t, $J = 3.6\text{Hz}$), 4.36-4.50 (2H, ABq, $J = 11.7\text{Hz}$), 6.91 (1H, s), 6.96 (2H, s) and 7.16-7.57 (5H, m).

- 18 -

d) 1-(3,5-Dimethylbenzyloxy)-2-phenylsulphenimine cyclohexane (Example 1c, 5.80g) was dissolved in ether (100ml) at 0°C. Phenyllithium (17.1ml) was added and after 1 hour the reaction mixture was heated to reflux. The reaction was
5 quenched with 2M-sodium hydroxide (100ml) and the product extracted into ethyl acetate (3 x 50ml). The combined organic phase was washed with water (2 x 50ml), saturated sodium chloride (50ml), dried ($MgSO_4$) and evaporated in vacuo. The product was purified on silica eluting with petroleum ether-ethyl
10 acetate mixtures to give 1-(3,5-dimethylbenzyloxy)-2-amino-2-
phenylcyclohexane as a crystalline solid. mp = 75-78°C. 1H NMR (360MHz, $CDCl_3$) δ 1.18-1.23 (2H, m), 1.25-1.31 (1H, m),
1.42-1.48 (2H, m), 1.88-1.92 (1H, m), 2.03-2.10 (1H, m), 2.24 (6H,
s), 2.34-2.38 (1H, m), 4.38 (1H, brs), 4.45, 4.51 (2H, ABq, J =
15 11Hz), 6.88 (2H, s), 6.90 (1H, s), 7.15-7.25 (3H, m) and 7.47-7.49
(2H, m). Found: C, 65.88; H, 7.67; N, 3.39; $C_{21}H_{27}NO$.
 $C_2H_2O_4$ (H_2O) requires C, 66.16; H, 7.48; N, 3.36%.

EXAMPLE 2

20

1-(3,5-Dimethylbenzyloxy)-2-dimethylamino-2- phenylcyclohexane

To a solution of acetic acid (1.6ml) formaldehyde (1.10ml)
and sodium cyanoborohydride (0.7g) was added 1-(3,5-
25 dimethylbenzyloxy)-2-amino-2-phenylcyclohexane (1.7g, Example
1d) in methanol. After stirring the solution for 2 hours, ethyl
acetate and water was added and the organic phase dried
($MgSO_4$). Evaporation of the solvent in vacuo and column

- 19 -

chromatography on silica gel (eluting with petroleum ether-ethyl acetate mixtures) gave the title compound. ^1H NMR (360MHz, CDCl_3) δ 1.18-1.25 (4H, m), 1.56-1.64 (2H, m), 1.99 (6H, s), 2.02-2.10 (1H, m), 2.32 (6H, s), 2.37-2.49 (1H, m), 4.10-4.13 (1H, m),
5 4.50, 4.69 (2H, ABq, $J = 11.8\text{Hz}$), 6.93 (1H, s), 7.07 (2H, s) and
7.17-7.33 (5H, m). Found: C, 80.56; H, 9.06; N, 4.39;
 $\text{C}_{23}\text{H}_{31}\text{NO}$. (0.25) H_2O requires C, 80.77; H, 9.28; N, 4.09%.

EXAMPLE 3

10

1-(3,5-Dimethylbenzyloxy)-2-methoxycarbonylmethylamino- 2-phenylcyclohexane

A solution of 1-(3,5-dimethylbenzyloxy)-2-amino-2-phenylcyclohexane (0.6g, Example 1d), methylbromoacetate (0.38ml) and triethylamine (0.54ml) in tetrahydrofuran (30ml)
15 was heated to reflux for 6 hours. After evaporation of the solvent the residue was redissolved in ethyl acetate (50ml) which was washed with water (50ml), saturated sodium chloride (50ml), dried (MgSO_4) and evaporated in vacuo. The residue
20 was purified by column chromatography on silica gel eluting with petroleum ether-ethyl acetate mixtures to give the title compound. ^1H NMR (250MHz, CDCl_3) δ 1.20-1.35 (2H, m), 1.58-1.84 (4H, m), 1.88-2.0 (2H, m), 2.24 (6H, s), 3.16, 3.24 (2H, ABq,
 $J = 15\text{Hz}$), 3.50 (1H, m), 3.71 (3H, s), 4.08, 4.31 (2H, ABq, $J =$
25 12Hz), 6.68 (2H, s), 6.84 (1H, s) and 7.22-7.48 (5H, m).

- 20 -

EXAMPLE 4

1-(3,5-Dimethylbenzyloxy)-2-(carboxamido)methylamino-2-phenylcyclohexane

5 Ammonia gas was bubbled through a cooled solution of 1-(3,5-dimethylbenzyloxy)-2-methoxycarbonylmethylamino)-2-phenylcyclohexane (0.38g, Example 3) in methanol (20ml). After 16 hours the solvent was removed in vacuo and the residue purified by column chromatography on silica gel eluting with
10 petroleum ether-ethyl acetate mixtures to give the title compound; m/e FAB 368 (M+H). ^1H NMR (360MHz, CDCl_3) δ 1.37-1.40 (2H, m), 1.58-1.94 (6H, m), 2.15 (6H, s), 2.78-2.83 (2H, m), 2.93-2.99 (1H, m), 3.40-3.42 (1H, m), 3.89, 4.22 (2H, ABq, $J = 11.8\text{Hz}$), 6.50 (2H, s), 6.79 (1H, s), 7.01 (1H, brs) and 7.21-7.42 (5H, m).

The oxalate salt was recrystallised from ethanol/water. mp 72-76°C. Found: C, 63.80; H, 7.06; N, 5.54; $\text{C}_{23}\text{H}_{30}\text{N}_2\text{O}_2 \cdot 1.25(\text{C}_2\text{H}_2\text{O}_4)$ requires C, 63.93; H, 6.83; N, 5.84%.

20

EXAMPLE 5

1-(Bis-3,5-trifluoromethylbenzyloxy)-2-amino-2-phenylcyclohexane

25 The title compound was prepared using an analogous procedure as outlined in Example 1 but using Bis-3,5-trifluoromethylbenzyl alcohol. ^1H NMR (360MHz, DMSO) δ

- 21 -

1.40-1.52 (2H, m), 2.61-2.73 (2H, m), 2.78-2.84 (2H, m), 1.98-
2.04 (1H, m), 2.06-2.09 (1H, m), 4.02 (1H, t, J = 6.3Hz), 4.50,
4.79 (2H, ABq, J = 12.9Hz), 7.33-7.43 (3H, m), 7.59-7.61 (2H, m),
7.85 (2H, s) and 7.96 (1H, s). The oxalate salt was recrystallised
5 from ethanol/water mp 119-122°C. Found: C, 53.96; H, 4.48; N,
2.70; $C_{21}H_{21}F_6NO.C_2H_2O_4.(0.25)H_2O$; C, 53.96; H, 4.62; N,
2.73%.

EXAMPLE 6

10

1-(Bis-3,5-trifluoromethylbenzyloxy)-2-(carboxamido)methylamino-2-phenylcyclohexane

The title compound was prepared using an analogous procedure as outlined in Example 4. 1H NMR (360MHz, DMSO)
15 δ 1.30-1.44 (2H, m), 1.48-1.58 (1H, m), 1.59-1.64 (2H, m), 1.84-
2.06 (2H, m), 2.08-2.16 (2H, m), 2.96, 3.12 (2H, ABq, J =
15.6Hz), 4.04-4.14 (1H, m), 4.43, 4.75 (2H, ABq, J = 12.6Hz),
7.30-7.56 (5H, m), 7.90 (2H, s) and 7.98 (1H, s). The oxalate salt
was recrystallised in ethanol/water mp = 48-50°C. Found: C,
20 54.65; H, 5.19; N, 4.88 requires
 $C_{23}H_{22}N_2O_2F_6.(0.6)C_2H_2O_4.(0.25)H_2O$; C, 54.53; H, 4.86; N,
5.25%.

EXAMPLE 7

25

1,5-Bis-(3,5-dimethylbenzyloxy)-2-amino-2-phenylcyclohexane

- 22 -

The title compound was prepared using an analogous procedure as outlined in Example 1 using 4-(3,5-dimethylbenzyloxy)cyclohexene oxide. ^1H NMR (360MHz, DMSO) δ 1.44-1.68 (2H, m), 1.68-2.10 (4H, m), 2.19 (6H, s), 2.23 (6H, s), 2.40-2.51 (2H, m), 3.58-3.65 (1H, m), 3.68-3.75 (1H, m), 4.10-4.43 (4H, m) and 6.60-7.62 (11H, m). The oxalate salt was recrystallised in petroleum ether-ethyl acetate. mp = 103-105°C. Found: C, 69.66; H, 7.45; N, 2.53, requires C₃₀H₃₇NO₂.C₂H₂O₄.(0.25)H₂O; C, 69.36; H, 7.18; N, 2.52%.

- 23 -

The following examples illustrate pharmaceutical compositions according to the invention.

EXAMPLE 8A Tablets containing 1-25mg of compound

		<u>Amount mg</u>		
5	Compound of formula (I)	1.0	2.0	25.0
	Microcrystalline cellulose	20.0	20.0	20.0
	Modified food corn starch	20.0	20.0	20.0
	Lactose	58.5	57.5	34.5
10	Magnesium Stearate	0.5	0.5	0.5

EXAMPLE 8B Tablets containing 26-100mg of compound

		<u>Amount mg</u>		
15	Compound of formula (I)	26.0	50.0	100.0
	Microcrystalline cellulose	80.0	80.0	80.0
	Modified food corn starch	80.0	80.0	80.0
	Lactose	213.5	189.5	139.5
	Magnesium Stearate	0.5	0.5	0.5

20 The compound of formula (I), cellulose, lactose and a portion of the corn starch are mixed and granulated with 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 1.0mg, 2.0mg, 25.0mg, 26.0mg, 50.0mg and 100mg of the active compound per tablet.

EXAMPLE 9 Parenteral injection

		<u>Amount mg</u>
30	Compound of formula (I)	1 to 100mg
	Citric Acid Monohydrate	0.75mg
	Sodium Phosphate	4.5mg
	Sodium Chloride	9mg
	Water for Injections	to 1ml

- 24 -

The sodium phosphate, citric acid monohydrate and sodium chloride are dissolved in a portion of the water. The compound of formula (I) is dissolved or suspended in the solution and made up to volume.

5


EXAMPLE 10 Topical formulation

	<u>Amount mg</u>
	Compound of formula (I)
	1-10g
	Emulsifying Wax
10	30g
	Liquid paraffin
	20g
	White Soft Paraffin
	to 100g
	The white soft paraffin is heated until molten. The liquid paraffin and emulsifying wax are incorporated and stirred until dissolved. The compound of formula (I) is added and stirring continued until dispersed. The mixture is then cooled until solid.
15	

- 25 -

CLAIMS:

1. A compound of formula (I), or a salt or
 5 prodrug thereof:



(I)

15 wherein

X represents O or S;

R¹ represents phenyl optionally substituted by
 1, 2 or 3 groups selected from C₁-6alkyl, C₂-6 alkenyl,
 C₂-6alkynyl, halo, cyano, nitro, trifluoromethyl,
 20 trimethylsilyl, -OR^a, SR^a, SOR^a, SO₂R^a, -NR^aR^b, -NR^aCOR^b,
 -NR^aCO₂R^b, -CO₂R^a or -CONR^aR^b;

R² represents phenyl optionally substituted by
 C₁-6alkyl, C₁-6alkoxy, halo or trifluoromethyl;

R³ and R⁴ each independently represent H, COR^a,
 25 CO₂R^a or C₁-6alkyl optionally substituted by a group
 selected from (CO₂R^a, CONR^aR^b, hydroxy, cyano, COR^a,
 NR^aR^b, and phenyl optionally substituted by C₁-6alkyl,
 C₁-6alkoxy, halo or trifluoromethyl);

R⁵ represents H or XCH₂R⁶ wherein R⁶ represents
 30 phenyl optionally substituted by 1, 2 or 3 groups
 selected from C₁-6alkyl, C₂-6 alkenyl, C₂-6alkynyl, halo,
 cyano, nitro, trifluoromethyl, trimethylsilyl, -OR^a, SR^a,
 SOR^a, SO₂R^a, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -CO₂R^a or
 -CONR^aR^b and X is as previously defined;

- 26 -

R⁷ and R⁸ each independently represent H or C₁₋₆alkyl; and

R^a and R^b each independently represent H, C₁₋₆alkyl, phenyl or trifluoromethyl.

5

2. A compound as claimed in claim 1 wherein R⁷ and R⁸ each represent H.

10 3. A compound as claimed in claim 1 or claim 2 wherein X represents O.

4. A compound as claimed in any preceding claim wherein R¹ represents phenyl substituted by one or more methyl or trifluoromethyl groups.

15

5. A compound as claimed in any preceding claim wherein R² represents unsubstituted phenyl.

20 6. A compound as claimed in any preceding claim wherein one of R³ and R⁴ represents H and the other of R³ and R⁴ represents H or CH₂CONH₂.

25 7. A compound as claimed in any preceding claim wherein R⁵ is H.

25

8. A compound as claimed in claim 1 selected from:

1-(3,5-dimethylbenzyl)oxy)-2-amino-2-phenylcyclohexane;

1-(3,5-dimethylbenzyl)oxy)-2-dimethylamino-2-

30 phenylcyclohexane;

1-(3,5-dimethylbenzyl)oxy)-2-methoxycarbonylmethylamino-2-phenylcyclohexane;

1-(3,5-dimethylbenzyl)oxy)-2-(carboxamido)methylamino-2-phenylcyclohexane;

- 27 -

1-(bis-3,5-trifluoromethylbenzyloxy)-2-amino-2-phenylcyclohexane;

1-(bis-3,5-trifluoromethylbenzyloxy)-2-(carboxamido)methylamino-2-phenylcyclohexane;

5 1,5-bis-(3,5-dimethylbenzyloxy)-2-amino-2-phenylcyclohexane;


and salts and prodrugs thereof.

9. A compound as claimed in any preceding
10 claim for use in therapy.

10. A pharmaceutical composition comprising a compound as claimed in any of claims 1 to 8 in association with a pharmaceutically acceptable carrier.

15

11. A process for the preparation of a compound as claimed in claim 1 which process comprises reacting a compound of formula (II):



(II)

wherein R¹, R⁵, R⁷, R⁸ and X are as defined for formula (I) and R³⁰ represents an alkyl or a phenyl group, with a reagent of formula R²-M, where R² is as defined for formula (I) and M represents an alkali metal.

30

12. A method for the treatment or prevention of a physiological disorder associated with an excess of

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB93/01961

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 12-15 are directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the compounds.
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 93/01961

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0436334	10-07-91	WO-A-	9109844	11-07-91
		EP-A-	0558156	01-09-93
EP-A-0499313	19-08-92	JP-A-	5078354	30-03-93
		US-A-	5242930	07-09-93
		CA-A-	2060949	12-08-92

16x2

THIS PAGE BLANK (USPTO)